Document is current
Any future updates will be listed below
-
Authors
Mazzitelli, Jose A. https://orcid.org/0000-0002-3896-3553
Pulous, Fadi E.
Smyth, Leon C. D.
Kaya, Zeynep https://orcid.org/0000-0003-4764-8624
Rustenhoven, Justin
Moskowitz, Michael A. https://orcid.org/0000-0002-9052-4937
Kipnis, Jonathan https://orcid.org/0000-0002-3714-517X
Nahrendorf, Matthias https://orcid.org/0000-0002-4021-1887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS127808)
- License Information
-
More Information
Article History
Received: 16 November 2022
Accepted: 10 October 2023
First Online: 23 November 2023
Competing interests
: J.K. is a scientific advisor for Sana Biotechnology. M.N. has received funds or material research support from Alnylam, Biotronik, CSL Behring, GlycoMimetics, GSK, Medtronic, Novartis and Pfizer, as well as consulting fees from Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon, Verseau Therapeutics and Bitterroot. The other authors declare no competing interests.
